Advanced Phase Chronic Myeloid Leukemia Treatment and Transplantation

Abstract

Imatinib and second generation tyrosine kinase inhibitors has dramatically improved outcomes in patients with chronic myeloid leukemia but allogeneic hematopoietic stem cell transplantation remains an important treatment option in patients who failed imatinib and or second generation second generation tyrosine kinase inhibitors or progressed accelerated and blastic phase. This article provides recommendations regarding the selection of allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia based on the evaluation of published articles and expert recommendations.

Anticancer Effects of Heterocyclic Schiff Base Ligands and Their Metal Complexes on Leukemia Cells

“…However, the applicability of such traditional chemotherapeutic approaches is primarily limited due to acquired Multi-Drug Resistance (MDR) in cells, which is acquired through the production of anti-apoptotic cascades and the overexpression of cell membranebased drug efflux pumps, such as P-glycoprotein, for self-defense. MDR-associated protein 1 is a protein that has a big impact on the intracellular availability of MDR-prone medicines [6,7] . MDR is accountable for more than 90 % of cancer deaths who are using traditional chemotherapeutics or novel targeted therapies.…”

The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors

“…In this supplementary issue of UHOD, the selections of second generation TKIs 21 , their long-term adverse effects with proper follow-up and management 22 , treatment of advanced-phase CML with focus on transplantation 23 , and current problems in the management of chronic myeloid leukemia in Turkey 24 have been summarized. Near future holds promise for the better CML management, operational cure of CML, or even cure of the disease with the discontinuation of TKI and/or targeting CML stem cell.…”